Skip to content

A study to evaluate the efficacy and safety of DTG+3TC in ART initial treatment HIV patients with baseline viral load higher than 500000

A study to evaluate the efficacy and safety of DTG+3TC in ART initial treatment HIV patients with baseline viral load higher than 500000

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074854
Enrollment
Unknown
Registered
2023-08-17
Start date
2023-09-01
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immune Deficiency Sydrome

Interventions

viral load >500 000copies/ml:Ttreat with DTG+3TC
viral load< 500 000copies/ml:treat with DTG+3TC

Sponsors

Shanghai Public Health Clinical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age not less than 18 years old; 2) HIV antibody is positive by ELISA and Western Blot, or HIV Viral load = 5000 copies/mL; 3) Have baseline Viral load detection data, and in addition, have at least one Viral load detection result; 4) The DTG+3TC scheme is the initial start-up scheme.

Exclusion criteria

Exclusion criteria: 1) Patients who refuse to provide ICF; 2) No baseline Viral load test result, or only one baseline Viral load test result; 3) Known resistance to Dolutegravir and Lamivudine. 4) Other situations that the researchers believe are not suitable for research.

Design outcomes

Primary

MeasureTime frame
viral load;;

Secondary

MeasureTime frame
CD4+T ;Whole blood cell count;adverse event;

Countries

China

Contacts

Public ContactJun Chen

Shanghai Public Health Clinical Center

qtchenjun@163.com+86 180 1750 0639

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026